Duane DeSisto is the Chief Executive Officer of Insulet Corporation, a company focused on developing advanced insulin delivery systems. He joined Insulet in 2003, and since then, he has played a key role in leading the company through significant growth...

Duane DeSisto is the Chief Executive Officer of Insulet Corporation, a company focused on developing advanced insulin delivery systems. He joined Insulet in 2003, and since then, he has played a key role in leading the company through significant growth and innovation. Before that, he held various finance and leadership positions, including Chief Financial Officer at ZOLL Medical Corporation, where he helped drive growth in medical devices. Duane's experience in the medical technology industry goes back over two decades, giving him a rich background in both finance and operations. One notable aspect of his tenure at Insulet includes a solid compensation package, with a total of over $9 million in 2017, primarily tied to the company’s performance. Interestingly, he has also served as a director at Stereotaxis, Inc., expanding his leadership experience beyond Insulet. He consistently participates in insider trading, showcasing his deep commitment and confidence in the company’s future. His strategic vision is clearly aimed at making innovative improvements in diabetes care, which reflects his broader mission to make a significant impact in the medical field.